|
|
ANN ARBOR, Mich. (February 18, 2009) – NanoBio Corp., a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines, announced today that it has acquired $12 million in series B equity financing with Perseus LLC and other existing investors. To date, over $80 million in funding has been directed toward the development of the company’s NanoStatTM technology platform.
The series B funding will be used by the company to complete a phase 1 study investigating
Continue reading: NanoBio Corporation Raises $12 Million in Series B Financing
ANN ARBOR, Mich. (Jan. 29, 2009) – Scientists at NanoBio Corp. and the University of Michigan have demonstrated in the laboratory that their novel topical nanoemulsion kills the highly resistant strains of bacteria that cause chronic illness and death among individuals with cystic fibrosis.
The findings are significant because they represent a new model for treating resistant bacteria that lead to pulmonary failure in patients with cystic fibrosis, according to the study authors. Results of the
Continue reading: Nanoemulsion Kills Highly Resistant Bacteria Found in Patients with Cystic Fibrosis
Ann Arbor, MI (September 10, 2008) – Donald Nease, Jr., MD, Chief Medical Officer for Cielo MedSolutions, authored a paper in Medical Care entitled “Impact of a Generalizable Reminder System on Colorectal Cancer Screening in Diverse Primary Care Practices.” The paper reports on a study evaluating ClinfoTracker – the technology on which Cielo ClinicTM is based – using historical control data in twelve community-based, primary care practices distributed across Michigan.
Average screening rates at the beginning
Continue reading: Cielo MedSolutions’ Technology Improves Colorectal Screening Rates
ANN ARBOR, Mich., Jun 17, 2008 – Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced plans to initiate a 40 patient U.S. Phase II clinical trial to study the use of Cardiac Repair Cells (CRCs), a mixture of stem and progenitor cells derived from a patient’s own bone marrow, for the treatment of dilated cardiomyopathy (DCM), a severe form of chronic heart failure. Aastrom is now authorized under U.S. Food & Drug Administration
Continue reading: Aastrom to Initiate Phase II Clinical Trial Using Cardiac Repair Cells
ANN ARBOR, Mich., Apr 17, 2008 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced encouraging data from the first two compassionate use patients treated with the Company’s autologous stem cell therapy for dilated cardiomyopathy (DCM), a type of severe chronic heart failure. Hans Michael Klein, M.D., Professor of Cardiac Surgery at the Dusseldorf University Hospital in Dusseldorf, Germany performed the first human application of Aastrom’s Cardiac
Continue reading: Aastrom Biosciences Announces Stem Cell Results
|
|
Loading ...